While Clinicians’ Awareness of and Familiarity with Optimer/Cubist’s Dificid Has Increased Since Product Launch, Cost Cont

Results from a survey fielded three months after commercial launch of Dificid (fidaxomicin) find that approximately half of clinicians have already prescribed Dificid to their Clostridium difficile-associated disease (CDAD) patients

EXTON, Pa.--(BUSINESS WIRE)-- Arlington Medical Resources (AMR) and BioTrends Research Group find that three months post-launch of Dificid, approximately half of surveyed infectious disease (ID) specialists and internists have initiated Optimer/Cubist’s Dificid in at least one patient since product launch, with three-quarters of patients having disease classified as severe or severe/complicated. Furthermore, roughly half of physicians who have not already used Dificid anticipate prescribing it in the next 3 months; patients with severe or severe/complicated CDAD and those experiencing recurrent, resistant infection continue to be viewed as the most likely candidates for the drug.

In agreement with results from wave 1 of this LaunchTrends® Institutional: Dificid report series, Dificid’s sustained clinical response rate and efficacy continue to be regarded by physicians as its greatest advantages when compared to other currently available treatment options for CDAD. However, the cost of Dificid ($2,800 for a 10-day course) still comes as a surprise to many physicians and is seen as the most significant obstacle to the drug’s use. Lack of inclusion on hospital formulary is also perceived as a barrier to prescribing Dificid to more patients.

ID specialists and internists still regard oral vancomycin as the therapy most likely to be displaced by Dificid, with roughly 50 percent of physicians indicating that their use of oral vancomycin will decrease now that Dificid is commercially available. Dificid is expected to displace oral vancomycin in both the hospital and nursing home/long-term care setting.

About LaunchTrends Institutional

LaunchTrends® Institutional: Dificid is a series of four syndicated reports designed to track perceptions and anticipated use of Optimer/Cubist’s Dificid at pre-launch and uptake of the drug three months, six months, and twelve months following launch. LaunchTrends® Institutional assesses trial and use of new products, barriers to use, reasons to use, typical patient types, line of therapy, product perceptions, promotional efforts/messages, and product satisfaction. In the current wave of research, AMR surveyed 53 ID specialists and 53 internists and conducted qualitative interviews with a subset of 20 of the responders in November 2011.

About BioTrends Research Group, LLC

BioTrends Research Group, LLC provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.



CONTACT:

BioTrends Research Group, LLC
Todd Samuelson, 610-321-9432
[email protected]
or
Decision Resources Group
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Hospitals  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.